^
Association details:
Biomarker:MYC overexpression
Cancer:Non Small Cell Lung Cancer
Drug Class:ROS1 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer

Published date:
05/04/2022
Excerpt:
Using complementary approaches in multiple models, including a MYC-amplified patient-derived cell line and xenograft (LUAD-0006), we established that MYC overexpression induces broad ROS1-TKI resistance….This study functionally characterizes MYC overexpression as a novel form of therapeutic resistance to ROS1 tyrosine kinase inhibitors in non–small cell lung cancer...
DOI:
10.1158/1541-7786.MCR-22-0025